Avalon Ventures XI Updates Janux Therapeutics Stake

TL;DR

Avalon Ventures XI now holds 5.3% of Janux Therapeutics after filing an amendment.

AI Summary

Avalon Ventures XI, L.P. and its affiliates have filed an amendment (No. 5) to their Schedule 13D regarding Janux Therapeutics, Inc. as of October 22, 2024. The filing indicates a change in beneficial ownership, with Avalon Ventures XI, L.P. now holding 1,900,000 shares of common stock, representing approximately 5.3% of the outstanding shares. This filing is an update to their previous disclosures.

Why It Matters

This filing signals a potential shift in significant ownership for Janux Therapeutics, which could influence stock price and corporate strategy.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership by significant investors can lead to increased volatility and potential strategic shifts for the company.

Key Numbers

• 1,900,000 — Shares Held (Beneficial ownership by Avalon Ventures XI, L.P.)
• 5.3% — Ownership Percentage (Represents the stake held by Avalon Ventures XI, L.P.)

Key Players & Entities

• Avalon Ventures XI, L.P. (company) — Filing entity
• Janux Therapeutics, Inc. (company) — Subject company
• 1,900,000 (dollar_amount) — Number of shares held
• 5.3% (dollar_amount) — Percentage of shares held
• October 22, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 47103

Filing Documents

• tm2426635d1_sc13da.htm (SC 13D/A) — 340KB
• tm2426635d1_ex99a.htm (EX-99.A) — 7KB
• 0001104659-24-110567.txt ( ) — 350KB

Purpose of Transaction

Item 4. Purpose of Transaction

of the Statement is hereby amended and supplemented as follows

Item 4 of the Statement is hereby amended and supplemented as follows: At 11:59 pm ET on October 15, 2024, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired. All closing conditions were satisfied, and the transactions contemplated by the Stock Purchase Agreement were consummated, on October 18, 2024.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer

of the Statement is hereby amended and restated as follows

Item 5 of the Statement is hereby amended and restated as follows: (a)– (b). The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of October 21, 2024: Reporting Persons Shares Held Directly Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Beneficial Percentage of Class (6) Avalon Ventures (1) 2,071,799 2,071,799 2,071,799 2,071,799 4.0 % ABV SPV (2) 2,115,373 2,115,373 2,115,373 2,115,373 4.0 % ABV I (3) 401,321 401,321 401,321 401,321 0.8 % Avalon XI GP (1) 2,071,799 2,071,799 2,071,799 4.0 % ABV SPV GP (2) 2,115,373 2,115,373 2,115,373 4.0 % ABV GP (3) 401,321 401,321 401,321 0.8 % Kinsella (1) 2,071,799 2,071,799 2,071,799 4.0 % Levandov (1) 5,651 5,

View Full Filing

View this SC 13D/A filing on SEC EDGAR